Starting January 1, FDA grants BAVENCIO® (avelumab) injection the following permanent HCPCS J-Code:J9023
J-code Now Available for TECENTRIQ® (atezolizumab)
FDA Approves Genentech’s Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer
GAZYVA Now Approved for Previously
Untreated Follicular Lymphoma
PFIZER RECEIVES FDA APPROVAL FOR SUTENT® (SUNITINIB MALATE) AS FIRST AND ONLY ADJUVANT TREATMENT FOR ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA
Follow RMOS on Twitter
What's New @ RMOS:
RMOS Sponsors Colorado Cancer Coalition Symposium. Register Today!
Did You Miss Our Symposium on Immune-Related Adverse Events (irAEs)? Get Access to the Recording!
RMOS Submits Letter Regarding Medicare Part B to Department of Health and Human Services
AstraZeneca's TAGRISSO® (osimertinib) Receives FDA Full Approval
| ACCC Resources
| ASCO Resources
| ASCO Connection |
© Oncology State Society Network. All rights reserved.